• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low-dose vemurafenib in hairy cell leukemia patients with active infection.

作者信息

Bohn Jan-Paul, Pircher Andreas, Wanner David, Vill David, Foeger Bernhard, Wolf Dominik, Steurer Michael

机构信息

Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Department of Internal Medicine, Academic Teaching Hospital Hall, Hall, Austria.

出版信息

Am J Hematol. 2019 Jun;94(6):E180-E182. doi: 10.1002/ajh.25474. Epub 2019 Apr 4.

DOI:10.1002/ajh.25474
PMID:30916799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6593695/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe7a/6593695/495e8fdbd045/AJH-94-E180-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe7a/6593695/495e8fdbd045/AJH-94-E180-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe7a/6593695/495e8fdbd045/AJH-94-E180-g001.jpg

相似文献

1
Low-dose vemurafenib in hairy cell leukemia patients with active infection.低剂量维莫非尼用于患有活动性感染的毛细胞白血病患者。
Am J Hematol. 2019 Jun;94(6):E180-E182. doi: 10.1002/ajh.25474. Epub 2019 Apr 4.
2
Partial response in hairy cell leukemia with vemurafenib despite early discontinuation due to agranulocytosis.尽管因粒细胞缺乏症而早期停药，维莫非尼仍可使毛细胞白血病出现部分缓解。
Anticancer Drugs. 2020 Feb;31(2):196-198. doi: 10.1097/CAD.0000000000000821.
3
Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.毛细胞白血病诊断时的皮肤白细胞破碎性血管炎经维莫非尼和利妥昔单抗成功治疗。
Leuk Res. 2021 May;104:106571. doi: 10.1016/j.leukres.2021.106571. Epub 2021 Mar 30.
4
Targeted therapy for treatment of patients with classical hairy cell leukemia.针对经典型毛细胞白血病患者的靶向治疗。
Leuk Res. 2021 Mar;102:106522. doi: 10.1016/j.leukres.2021.106522. Epub 2021 Feb 4.
5
Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.两名难治性毛细胞白血病患者接受单药维莫非尼治疗后的继发性恶性肿瘤。
Leuk Lymphoma. 2019 May;60(5):1331-1333. doi: 10.1080/10428194.2018.1519809. Epub 2018 Oct 15.
6
Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia.维莫非尼致复发性毛细胞白血病患者胰腺炎。
BMJ Case Rep. 2020 Sep 14;13(9):e236073. doi: 10.1136/bcr-2020-236073.
7
Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib.经典型毛细胞白血病并发全血细胞减少症和严重感染：维莫非尼治疗 3 例报告。
Blood Adv. 2019 Jan 22;3(2):116-118. doi: 10.1182/bloodadvances.2018027466.
8
Targeting MEK in vemurafenib-resistant hairy cell leukemia.在维莫非尼耐药的毛细胞白血病中靶向MEK
Leukemia. 2019 Feb;33(2):541-545. doi: 10.1038/s41375-018-0270-2. Epub 2018 Oct 19.
9
Response of relapsed central nervous system hairy cell leukemia to vemurafenib.复发的中枢神经系统毛细胞白血病对维莫非尼的反应。
Leuk Lymphoma. 2016 Dec;57(12):2952-2954. doi: 10.1080/10428194.2016.1177773. Epub 2016 Apr 27.
10
Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.双等位基因BRAF V600E突变的毛细胞白血病对低剂量维莫非尼的快速反应
Br J Haematol. 2013 Apr;161(1):150-3. doi: 10.1111/bjh.12201. Epub 2012 Dec 29.

引用本文的文献

1
Unraveling alterations: molecular insights to circumvent therapeutic resistance across cancer types.揭示改变：跨越癌症类型规避治疗耐药性的分子见解。
Cancer Drug Resist. 2025 Mar 24;8:14. doi: 10.20517/cdr.2024.213. eCollection 2025.
2
Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group.毛细胞白血病和毛细胞白血病样疾病患者的管理建议：由法语专家和法国创新白血病组织（FILO）小组完成的一项工作
Cancers (Basel). 2024 Jun 10;16(12):2185. doi: 10.3390/cancers16122185.
3

本文引用的文献

1
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.维莫非尼低剂量治疗毛细胞白血病的 BRAF 抑制作用。
Blood. 2016 Jun 9;127(23):2847-55. doi: 10.1182/blood-2015-11-680074. Epub 2016 Mar 3.
2
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.靶向复发性或难治性毛细胞白血病中的突变型BRAF
N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.
3
Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.苯丁酸氮芥和克拉屈滨治疗毛细胞白血病的长期疗效。
Concomitantly Diagnosed Disseminated Infection and Hairy Cell Leukemia With Review of Pathophysiology.
同时诊断出的播散性感染和毛细胞白血病，并回顾了其病理生理学。
J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241253343. doi: 10.1177/23247096241253343.
4
Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.2013 年至 2022 年期间，在森梅威思大学内科和肿瘤学部，采用低剂量 vemurafenib 治疗难治/复发毛细胞白血病患者的长期随访结果。
Pathol Oncol Res. 2023 Nov 8;29:1611378. doi: 10.3389/pore.2023.1611378. eCollection 2023.
5
Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.毛细胞白血病及其他毛细胞样疾病的新型靶向治疗
Front Oncol. 2022 Dec 22;12:1068981. doi: 10.3389/fonc.2022.1068981. eCollection 2022.
6
A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A.一名毛细胞白血病患者接受聚乙二醇化干扰素-α-2A治疗成功
J Clin Med. 2022 Dec 27;12(1):193. doi: 10.3390/jcm12010193.
7
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.维莫非尼单药治疗复发/难治性毛细胞白血病患者的长期疗效。
Blood. 2022 Dec 22;140(25):2663-2671. doi: 10.1182/blood.2022016183.
8
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.毛细胞白血病（HCL）和变异型HCL（HCL-V）的进展：以依鲁替尼为重点的靶向治疗原理
Ther Adv Hematol. 2022 Apr 13;13:20406207221090886. doi: 10.1177/20406207221090886. eCollection 2022.
9
Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.毛细胞白血病（HCL）和 HCL 变异型：治疗进展的最新动态和亮点。
Curr Oncol Rep. 2022 Sep;24(9):1133-1143. doi: 10.1007/s11912-022-01285-1. Epub 2022 Apr 11.
10
Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General Population.毛细胞白血病患者的预期寿命正常——一项35年的单中心经验及与普通人群的比较。
Cancers (Basel). 2022 Feb 28;14(5):1242. doi: 10.3390/cancers14051242.
Leuk Lymphoma. 2011 Jun;52 Suppl 2:21-4. doi: 10.3109/10428194.2011.565093.
4
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.2008 年世界卫生组织淋巴造血组织肿瘤分类及以后：不断发展的概念和实际应用。
Blood. 2011 May 12;117(19):5019-32. doi: 10.1182/blood-2011-01-293050. Epub 2011 Feb 7.
5
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.用克拉屈滨治疗后的毛细胞白血病患者的长期随访
J Clin Oncol. 2003 Mar 1;21(5):891-6. doi: 10.1200/JCO.2003.05.093.